These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 16265690)

  • 1. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
    Chakravarty EF; Michaud K; Wolfe F
    J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis.
    Amari W; Zeringue AL; McDonald JR; Caplan L; Eisen SA; Ranganathan P
    Rheumatology (Oxford); 2011 Aug; 50(8):1431-9. PubMed ID: 21415022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
    Wolfe F; Caplan L; Michaud K
    Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders.
    Wolfe F; Michaud K; Chakravarty EF
    Rheumatology (Oxford); 2006 Nov; 45(11):1370-5. PubMed ID: 17003175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.
    Wolfe F; Hawley DJ
    J Rheumatol; 2000 Jul; 27(7):1668-73. PubMed ID: 10914849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry.
    Pallavicini FB; Caporali R; Sarzi-Puttini P; Atzeni F; Bazzani C; Gorla R; Marchesoni A; Favalli EG; Montecucco C
    Autoimmun Rev; 2010 Jan; 9(3):175-80. PubMed ID: 19647103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.
    van Lümig PP; Menting SP; van den Reek JM; Spuls PI; van Riel PL; van de Kerkhof PC; Fransen J; Kievit W; de Jong EM
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):752-60. PubMed ID: 25229823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
    Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
    J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
    Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
    Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
    Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients.
    Mackenzie KA; Wells JE; Lynn KL; Simcock JW; Robinson BA; Roake JA; Currie MJ
    Nephrol Dial Transplant; 2010 Jan; 25(1):300-6. PubMed ID: 19783601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
    Jacobsson LT; Turesson C; Gülfe A; Kapetanovic MC; Petersson IF; Saxne T; Geborek P
    J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
    Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
    JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy.
    Antohe JL; Bili A; Sartorius JA; Kirchner HL; Morris SJ; Dancea S; Wasko MC
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):215-21. PubMed ID: 21972198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.